Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets

ABSTRACT

Objective: To test the hypothesis that dimethyl fumarate (Tecfidera, BG-12) affects B-cell subsets in patients with relapsing-remitting multiple sclerosis (RRMS).

Methods: Peripheral blood B cells were compared for surface marker expression in patients with RRMS prior to initiation of treatment, after 4–6 months, and at more than 1 year of treatment with BG-12. Production of interleukin (IL)-10 by RRMS patient B cells was also analyzed.

Results: Total numbers of peripheral blood B lymphocytes declined after 4–6 months of BG-12 treatment, due to losses in both the CD27+ memory B cells and CD27neg B-cell subsets. Some interpatient variability was observed. In contrast, circulating CD24highCD38high (T2-MZP) B cells increased in percentage in the majority of patients with RRMS after 4–6 months and were present in higher numbers in all of the patients after 12 months of treatment. The CD43+CD27+ B-1 B cells also increased at the later time point in most patients but were unchanged at 4–6 months compared to pretreatment levels. Purified B cells from 7 of the 9 patients with RRMS tested after 4–6 months of treatment were able to produce IL-10 following CD40 ligand stimulation, and the amount corresponded with the combined levels of T2-MZP and B-1 B cells in the sample. None of the patients with RRMS in this study have had a relapse while taking BG-12.

Conclusions: These data suggest that BG-12 differentially affects B-cell subsets in patients with RRMS, resulting in increased numbers of circulating B lymphocytes with regulatory capacity.


GLOSSARY

CBC = complete blood count; DMF = dimethyl fumarate; EAE = experimental autoimmune encephalomyelitis; HO-1 = heme oxygenase-1; IL-10 = interleukin-10; MS = multiple sclerosis; Nrf2 = nuclear factor (erythroid-derived 2)-like 2; PBL = peripheral blood lymphocytes; PBMC = peripheral blood mononuclear cells; PML = progressive multifocal leukoencephalopathy; RRMS = relapsing-remitting multiple sclerosis; T2-MZP = transitional 2 marginal zone precursor.

Treatment of relapsing-remitting multiple sclerosis (RRMS) has advanced with the approval of new medications.1,2 BG-12 (Tecfidera; Biogen Idec, Cambridge, MA), an oral formulation of dimethyl fumarate (DMF), lowered relapse rates in clinical trials.3,4 Neuroprotective effects and ease of administration of BG-12 has led to increased use as a front-line treatment for RRMS.5–7 Recently reported cases of progressive multifocal leukoencephalopathy (PML) in DMF-treated patients with RRMS have raised concerns about the long-term safety of BG-12.8–10 In recent studies, BG-12 treatment led to decreases in CD4+ and CD8+ T cells and B cells.11,12 The mechanisms underlying these effects in RRMS are unknown; however, fumarates have induced lymphocyte apoptosis and elevated production of the immune suppressive cytokine interleukin-10 (IL-10).13–15 Major producers of IL-10 include regulatory CD4+ T lymphocytes (Treg) and B lymphocytes (Breg), which have moderated CNS inflammation in the experimental
autoimmune encephalomyelitis (EAE) mouse model.\textsuperscript{16,17} The effects of BG-12 treatment specifically on IL-10-producing lymphocytes have not been previously reported in patients with RRMS.

This prospective cohort study focused on testing the hypothesis that BG-12 treatment alters B-cell subtypes in patients with RRMS. Peripheral blood was collected from controls and patients with RRMS before and after treatment with oral BG-12. Total B-cell levels were reduced after treatment, with decreased levels of memory, immature, and naive B cells. In contrast, significant increases in the total numbers of CD24\textsuperscript{high}CD38\textsuperscript{high} B cells and CD27+CD43+ B cells were observed. These data demonstrate a novel way in which BG-12 may exert therapeutic effects in patients with RRMS.

**METHODS** Standard protocol approvals, registrations, and patient consents. Patients with a diagnosis of RRMS who had been prescribed BG-12 were enrolled in this prospective cohort study. Informed consent was obtained from all patients and controls prior to participation in the protocol, which was approved by the University of Michigan Institutional Review Board.

Demographics and blood samples. Patients were between 18 and 65 years of age, had not received another nonsteroidal disease-modifying therapy within the last 30 days, and had not had IV immunoglobulin therapy or plasmapheresis in the last 6 months. Four of 5 patients who had received oral or injected steroid treatments discontinued use more than 1 month before taking BG-12, and the other patient began a 6-week taper at the time of starting BG-12. Table 1 lists previous nonsteroidal medications taken by each patient and the time of discontinuation. Patients were put on a dose escalation schedule and all reached 240 mg BG-12 twice daily within 1–5 weeks of treatment initiation. A total of 13 patients with RRMS were followed longitudinally from pretreatment to 4–6 months of treatment with BG-12. A baseline peripheral blood sample was drawn within 2 months prior to initiation of BG-12, and after 4–6 months (20.5 ± 3.8 weeks) of reaching the standard dose of BG-12. Sex and age of the patients was 8/13 (61.5%) female, average age 48.0 years old (median 35; range 33–57). Eight of these patients had a follow-up sample taken after 12 months of treatment (see table 1). Peripheral blood mononuclear cells (PBMC) were also obtained from 6 healthy controls: 4/6 (66.7%) female, average age 46.0 ± 8.7 years (median 46.5; range 31–58). The 5 men were 40.4 ± 9.8 years old (median 35; range 33–57). Eight of these patients had a follow-up sample taken after 12 months of treatment (see table 1). Peripheral blood mononuclear cells (PBMC) were also obtained from 6 healthy controls: 4/6 (66.7%) female, average age 46.0 ± 8.7 years (median 46.5; range 31–58), and 2 men aged 31 and 49 years. Two female patients with RRMS and one female control were of African American descent. All other participants were non-Hispanic Caucasian. Blood samples (20–25 mL) from all participants were collected in sodium citrate cell culture tubes and processed immediately. Complete blood counts (CBCs) were obtained from the clinical pathology laboratory. Total B-cell numbers were calculated by multiplying percentages from flow cytometry and CBC lymphocyte counts.

Flow cytometry. Isolated PBMC from patients and controls were stained with monoclonal antibodies reactive against the cell surface markers CD19, CD27, and CD43 purchased from BD Biosciences (East Rutherford, NJ) and CD24 and CD38 from BioLegend (San Diego, CA). Multicolor flow cytometry was performed for all samples on a Beckman Coulter (Sharon Hill, PA) LSR flow cytometer using standardized voltage and compensation settings. Gating was determined using healthy control samples and was consistent throughout the study. Data analysis was performed using Tree Star (Ashland, OR) FlowJo version X.0.6 software.

Human B-cell culture and IL-10 analysis. Purified B cells were isolated from PBMC by magnetic bead separation using anti-human CD19 magnetic-activated cell sorting beads and the protocol provided by Miltenyi Biotec (Bergisch Gladbach, Germany). Labeled cells were positively selected over LS columns (Miltenyi Biotec) and were routinely >98% pure. B cells were cultured in high glucose Dulbecco Modified Eagle Medium supplemented with 10% heat-inactivated fetal calf serum, penicillin, streptomycin, insulin (5 µg/mL), and transferrin (50 µg/mL) with irradiated human CD40 ligand-transduced fibroblasts for 6 days. Cell-free supernatants were removed and analyzed for the presence of human IL-10 using OptEIA kit (BD Biosciences) following the manufacturer’s protocol. Concentrations of IL-10 were determined in comparison to standard curves.

Data collection and statistical analysis. Flow cytometry data were obtained from >20,000 lymphocytes from each sample. Statistics were performed using GraphPad (La Jolla, CA) Prism 6.01. Medians and interquartile ranges for each group were determined. Exact p values were calculated using the appropriate statistical tests for each dataset as indicated in the figure legends. Two-way analysis of variance with Dunn multiple comparison tests were used to establish statistical significance for datasets containing 3 or more groups. Comparisons of control and patient samples were performed using Mann-Whitney tests. Paired comparisons of time point data for individual patients were done using Wilcoxon matched-pairs signed-rank tests.

**RESULTS** BG-12 treatment reduced circulating memory and naive B cells. Treatment of RRMS with the Food and Drug Administration–approved oral drug, BG-12 (Tecfidera), is known to reduce total PBMC counts compared to pretreatment levels.\textsuperscript{3,18} Decreases involve both the T- and the B-lymphocyte populations, yet detailed analysis within these major lymphocyte lineages has not been reported.\textsuperscript{11,12} B cells can be subdivided into groups with distinct functions and states of activation that are distinguishable based on surface marker expression patterns.\textsuperscript{19} In this prospective cohort study, B-cell subsets were analyzed from 13 patients with RRMS (table 1) before and after 4–6 months of treatment with 240 mg twice daily oral BG-12. Eight patients were also tested after more than 1 year. Table 1 outlines the demographics and other clinical data for each patient including previous treatments and CBC lymphocyte counts. Patients 3, 4, 10, and 11 had taken oral or injected corticosteroids that were discontinued prior to starting BG-12 therapy. Patient 1 had a flare that was treated with...
Table 1  Patient demographics and clinical information

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age at baseline, y</th>
<th>Ethnicity</th>
<th>Pretreatment</th>
<th>Months before BG-12</th>
<th>CBC lymph (millions)</th>
<th>Months from BG-12 start</th>
<th>CBC lymph (millions)</th>
<th>&gt;12 Months sample</th>
<th>Months from BG-12 start</th>
<th>CBC lymph (millions)</th>
<th>Prior NS DMT</th>
<th>Time since previous DMT</th>
<th>Relapses after BG-12 started</th>
<th>Time since last relapse (prebaseline)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RRMS-1</td>
<td>F</td>
<td>53</td>
<td>C</td>
<td>–0.75</td>
<td>1.8</td>
<td>5</td>
<td>ND</td>
<td>26</td>
<td>0.8</td>
<td>None</td>
<td>26</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>0 mo*</td>
</tr>
<tr>
<td>RRMS-2</td>
<td>M</td>
<td>33</td>
<td>C</td>
<td>–2</td>
<td>4.0</td>
<td>4</td>
<td>1.1</td>
<td>15</td>
<td>1.6</td>
<td>Enbrel a</td>
<td>16 mo</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>8 mo</td>
</tr>
<tr>
<td>RRMS-3</td>
<td>M</td>
<td>56</td>
<td>C</td>
<td>–0.25</td>
<td>2.8</td>
<td>5</td>
<td>2.2</td>
<td>25</td>
<td>0.8</td>
<td>None</td>
<td>25</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>0.5 mo</td>
</tr>
<tr>
<td>RRMS-4</td>
<td>F</td>
<td>37</td>
<td>C</td>
<td>–0.75</td>
<td>0.8</td>
<td>4</td>
<td>0.6</td>
<td>23</td>
<td>0.8</td>
<td>None</td>
<td>23</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2 mo</td>
</tr>
<tr>
<td>RRMS-5</td>
<td>F</td>
<td>46</td>
<td>C</td>
<td>–2</td>
<td>2.0</td>
<td>4</td>
<td>1.2</td>
<td>20</td>
<td>1.5</td>
<td>Avonex</td>
<td>20</td>
<td>None</td>
<td>Unknown</td>
<td>None</td>
<td>Unknown</td>
</tr>
<tr>
<td>RRMS-6</td>
<td>F</td>
<td>51</td>
<td>AA</td>
<td>–1</td>
<td>2.7</td>
<td>4</td>
<td>1.4</td>
<td>ND</td>
<td>ND</td>
<td>Copaxone</td>
<td>13 mo</td>
<td>None</td>
<td>Unknown</td>
<td>None</td>
<td>Unknown</td>
</tr>
<tr>
<td>RRMS-7</td>
<td>M</td>
<td>35</td>
<td>C</td>
<td>0</td>
<td>2.3</td>
<td>4</td>
<td>1.5</td>
<td>20</td>
<td>1.6</td>
<td>Rebif</td>
<td>2 y</td>
<td>None</td>
<td>12 y</td>
<td>None</td>
<td>6 mo</td>
</tr>
<tr>
<td>RRMS-8</td>
<td>F</td>
<td>31</td>
<td>AA</td>
<td>–0.5</td>
<td>3.1</td>
<td>4</td>
<td>2.7</td>
<td>ND</td>
<td>ND</td>
<td>Avonex</td>
<td>1 mo</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2 y</td>
</tr>
<tr>
<td>RRMS-9</td>
<td>F</td>
<td>45</td>
<td>C</td>
<td>–5 a</td>
<td>1.5</td>
<td>4</td>
<td>0.8</td>
<td>ND</td>
<td>ND</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>4 mo</td>
<td>None</td>
<td>6 mo</td>
</tr>
<tr>
<td>RRMS-10</td>
<td>F</td>
<td>47</td>
<td>C</td>
<td>–0.5</td>
<td>1.5</td>
<td>6</td>
<td>0.7</td>
<td>16</td>
<td>0.6</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>4 mo</td>
<td>None</td>
<td>9 mo</td>
</tr>
<tr>
<td>RRMS-11</td>
<td>F</td>
<td>58</td>
<td>C</td>
<td>–0.5</td>
<td>1.6</td>
<td>4</td>
<td>1.9</td>
<td>13</td>
<td>1.7</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>9 mo</td>
</tr>
<tr>
<td>RRMS-12</td>
<td>M</td>
<td>34</td>
<td>C</td>
<td>0</td>
<td>2.8</td>
<td>6</td>
<td>1.6</td>
<td>ND</td>
<td>ND</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>2 mo</td>
<td>None</td>
<td>2 mo</td>
</tr>
<tr>
<td>RRMS-13</td>
<td>M</td>
<td>44</td>
<td>C</td>
<td>–0.25</td>
<td>2.9</td>
<td>5</td>
<td>1.5</td>
<td>ND</td>
<td>ND</td>
<td>Avonex</td>
<td>3 mo</td>
<td>None</td>
<td>3 mo</td>
<td>None</td>
<td>3 mo</td>
</tr>
</tbody>
</table>

Abbreviations: AA = African American; C = Caucasian; CBC = complete blood count; ND = not done; NS DMT = nonsteroidal disease-modifying therapy; RRMS = relapsing-remitting multiple sclerosis.

aPatient relapsed 1 week after baseline and took steroids until starting BG-12, then tapered off steroids over 6 weeks.
bEnbrel was taken for ankylosing spondylitis and discontinued 16 months prior to baseline pretreatment sample.
cRebif taken intermittently for 12 years, discontinued 1 month prior to baseline sample.
dPatient started BG-12 briefly at 0 months from pretreatment blood sample, then restarted 5 months later. Timing of other samples adjusted to restart date.
oral corticosteroids just prior to entering the study, and was tapered off of steroids immediately after BG-12 treatment was initiated.

Most (11 of 12) of the patients had a marked reduction in peripheral blood lymphocytes (PBL) after 4–6 months treatment with BG-12 compared to pretreatment levels (table 1). Levels of PBL did not decrease between the 4 and 6 months and >1 year time points for most patients. To determine the effects of BG-12 on B cells, flow cytometric analysis was performed on longitudinal samples from the patients with RRMS. Six healthy individuals who had similar demographics for age, sex, and ethnicity were used as controls. Figure 1A shows the gating used to select CD19+B cells from a representative patient (RRMS 8) at baseline and 4 months after starting BG-12. The majority of these patients with RRMS had an elevated percentage of CD19+B cells prior to BG-12 treatment compared to controls (figure 1B). A significant decrease in the total number of B cells was observed at 4–6 months of treatment compared to pretreatment levels (figure 1C and table 2). The total number of circulating CD19+B cells in the patients with RRMS did not significantly decrease between 4 and 6 months of treatment and more than 1 year of treatment (table 2).

Decreased circulating memory and naive B cells in BG-12-treated patients with RRMS. CD27 has been commonly used to distinguish activated/memory B cells from other B-cell subsets or activation states.19 CD19+CD27+ cells were analyzed before and after

**Figure 1** BG-12 treatment reduced total circulating B cells and had variable effects on memory B cells

Peripheral blood mononuclear cells (PBMC) isolated from patients with relapsing-remitting multiple sclerosis (RRMS) before and after BG-12 treatment and healthy controls were stained for B-cell markers. (A) Representative forward scatter, side scatter, and anti-CD19 staining from a single patient (RRMS 8) shows standardized gating for lymphocytes, single cells, and total CD19+B cells that was used for all of the samples. (B) Comparison of %CD19+B cells for healthy controls and patients with RRMS before treatment. Each dot represents an individual sample and lines are the median and interquartile range for each group. The exact *p* value shown below the title was calculated using Mann-Whitney test. (C) Total B-cell numbers/mL of blood for the patients with RRMS were calculated before and after 4–6 months of treatment by multiplying the %CD19+B cells by the lymphocyte counts reported by the clinical pathology laboratory (table 1). Lines connect individual patients. Exact *p* value for paired patient data was determined using Wilcoxon matched-pairs signed-rank test. (D) Representative histograms from patient RRMS-8 show gating used to define CD27+ memory B cells. (E) Percentages of CD27+ memory B cells in patients with RRMS before treatment compared with controls. Each dot represents data from one individual and lines are the median and interquartile range for each group. The *p* value was calculated using Mann-Whitney test. (F) Longitudinal %CD27+ memory B-cell data for individual patients with RRMS (n = 8) before, after 4–6 months, and after more than 1 year of treatment with BG-12.
treatment with BG-12 (figure 1, D–F). Patients with RRMS in this study had lower percentages of circulating CD27+ memory B cells prior to BG-12 treatment than the controls (figure 1E), suggesting that the CD27^{neg} B cells, which include a mixture of immature, transitional, and naïve B-cell subsets, were overrepresented in the patients with RRMS before treatment. As shown in figure 1F, there was some variability in the relative levels of memory vs naïve B cells in the patients with RRMS before treatment, and BG-12 had differential effects on the ratios. Treatment for 4–6 months led to decreases in the absolute number of circulating CD27^{+} B cells in all but one patient. The exception was patient RRMS-10, who went on to have fewer memory B cells after 1 year of treatment than at baseline (data not shown). Long-term treatment with BG-12 did not lead to further significant reductions in the total number of CD27^{+} B cells in most patients (table 2) or a consistent change in the ratio of CD27^{+} to CD27^{neg} B cells (figure 2C). Taken together, these results suggest that BG-12 treatment did not have a selective effect on either the CD27^{+} memory B cells or the CD27^{neg} immature, transitional, or naïve B cells, but that there was a generalized decrease of both B-lymphocyte populations in patients with RRMS.

Increased CD24^{high}CD38^{high} and CD43+CD27^{+} B cells after BG-12 treatment. The CD27^{neg} and CD27^{+} B-cell populations can be further subdivided into functionally distinct subsets. Notably, a subset of regulatory B cells that produce IL-10 has been found within the CD27^{neg} and CD27^{+} B-cell subsets. CD27^{neg} B cells that are CD24^{high}CD38^{high} (figure 2A) have been previously classified as transitional 2 marginal zone precursor (T2-MZP) B cells that produce IL-10.\textsuperscript{20,21} Circulating T2-MZP B cells were reduced in percentage in these patients with RRMS prior to treatment in comparison to controls (figure 2B). Unlike the total CD27^{neg} B-cell subset, increases in T2-MZP B cells were detected in 10 of 13 patients at 4–6 months treatment, and were higher than baseline in all 8 patients who were followed for more than 1 year (figure 2C). Despite reductions in total B cells, the number of circulating T2-MZP B cells tended to be higher after 4–6 months of BG-12 treatment and continued to increase over the longer term, resulting in significantly higher total T2-MZP B-cell numbers in the circulation of patients with RRMS after 1 year of BG-12 treatment (table 2).

The CD27^{+}CD43^{+} B-cell subset (figure 2D) has been identified as an innate-like B-1 B-cell subtype that, similar to its counterpart in mice, has the capacity to produce IL-10 and to regulate immune responses.\textsuperscript{22,23} Prior to treatment, B-1 B cells were found in the circulation at very low levels in all but one of the 13 patients with RRMS in our study in comparison to healthy controls (figure 2E). Despite the inclusion of patient RRMS-3, whose B-1 cells were within the normal range, the patients averaged a more than fourfold lower percentage of B-1 B cells than controls. The B-1 B cells responded somewhat differently to BG-12 treatment compared to T2-MZP B cells (figure 2F). After 4–6 months of treatment with BG-12, the percentage of circulating B-1 B cells was not significantly changed (figure 2F), and there was variability in the response from patient to patient. However, after 1 year of treatment, 6 of 8 patients with RRMS had a substantially higher percentage of B-1 B cells than what was present prior to BG-12 treatment. With the exception of patient RRMS-3, who had 48,800 B-1 B cells/mL of blood at baseline compared to the 4,200 \pm 3,700 B-1 B cells/mL average for the other 7 patients, there was a significant increase in the total number of circulating B-1 B cells after long-term treatment with BG-12 (table 2).

### Table 2: Total cell numbers of peripheral blood B-cell subsets

<table>
<thead>
<tr>
<th>B-cell subset</th>
<th>A: Pretreatment, cells/mL (n = 13)</th>
<th>B: 4-6 months BG-12, cells/mL (n = 12\textsuperscript{a})</th>
<th>C: &gt;12 months BG-12, cells/mL (n = 8\textsuperscript{b})</th>
<th>p Value, A vs C</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Major B-cell subsets</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total CD19+</td>
<td>211,000 ± 35,000</td>
<td>111,000 ± 19,000</td>
<td>95,000 ± 26,000</td>
<td>0.148</td>
</tr>
<tr>
<td>Total CD27+</td>
<td>57,000 ± 9,000</td>
<td>27,000 ± 6,000</td>
<td>23,000 ± 9,000</td>
<td>0.078</td>
</tr>
<tr>
<td><strong>Regulatory B-cell subsets</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD24^{high}CD38^{high}\textsuperscript{c}</td>
<td>5,600 ± 1,400</td>
<td>9,400 ± 3,000</td>
<td>12,000 ± 2,600</td>
<td>0.008\textsuperscript{b}</td>
</tr>
<tr>
<td>CD43^{+}CD27^{+} (no RRMS-3\textsuperscript{c})</td>
<td>4,200 ± 3,700</td>
<td>2,900 ± 600</td>
<td>8,200 ± 2,000</td>
<td>0.01\textsuperscript{b}</td>
</tr>
</tbody>
</table>

Abbreviations: CBC = complete blood count; RRMS = relapsing-remitting multiple sclerosis.

[a] Number of individuals varied based on sampling and available CBC lymphocyte counts (no 4-6 month CBC for RRMS-1).

[b] The p values for matched pairs were calculated using Wilcoxon tests; p < 0.02 was considered significant.

[c] Baseline CD43^{+}CD27^{+} for RRMS-3 was 12 SD away from the mean of other samples and was removed as outlier for all time points.
Not all T2-MZP or B-1 B cells produce IL-10 after stimulation, and patients with systemic lupus erythematosus had T2-MZP B cells that were defective in IL-10 production. To determine whether B cells from the patients with RRMS were functional, CD19+ B cells were purified using magnetic bead positive selection, and then cultured with a CD40 ligand-transduced cell line. This assay was dependent on having enough purified B cells, which was not achieved for all patients and time points. Figure 3A shows IL-10 data for the 3 patients with RRMS in this study who were analyzed at both the pretreatment and 4–6 months of BG-12 treatment time points. The percentages of T2-MZP and B-1 B cells in the sample prior to culture are shown in figure 3B. The results indicated that levels of IL-10...
produced by these 3 patients were comparable to the combined levels of T2-MZP and B-1 B cells before or after treatment, but not well-correlated with the individual subsets. A total of 9 patients with RRMS were analyzed for CD40 ligand-induced IL-10 production at the 4–6 months treatment time point (figure 3C).

While 7 of the 9 patients with RRMS released levels of IL-10 that correlated strongly with the percentage of T2-MZP plus B-1 B cells found in their blood, 2 patients with RRMS appeared to have a reduction in the expected levels of B-cell IL-10 production in this assay.

**DISCUSSION** Our data confirm that treatment of patients with RRMS with BG-12 leads to reductions in circulating lymphocytes, including B cells, as previously reported. Treatment with BG-12 was found to variably lower the total number of CD27+ memory B cells, as well as the CD27<sup>+</sup> immature, transitional, and naive B-cell subsets. In contrast, CD24<sup>hi</sup>CD38<sup>hi</sup> T2-MZP B cells increased in percentage after 4–6 months of treatment and remained higher in number than baseline in 8/8 (100%) patients after 1 year of treatment. Long-term treatment also led to increased numbers of circulating CD43+CD27+ B-1 cells. Both T2-MZP and B-1 B cells have been independently shown to produce the immune regulatory cytokine, IL-10, and the production of IL-10 by B cells in this study correlated with the combined presence of both of these cell subsets in 7/9 (78%) patients, while 2 patients failed to produce IL-10 despite relatively high levels of T2-MZP and B-1 cells. Thus, BG-12 treatment of patients with RRMS appeared to favor B cells that had immune regulatory potential.

The mechanisms underlying these differential effects of BG-12 on circulating B-lymphocyte subsets have not yet been determined. Some possibilities for the reductions in the majority of B cells include direct induction of apoptosis or indirect killing of B cells by other cells. Another possibility is that BG-12 may have initially affected TH cell viability or activation resulting in losses or changes to T-cell help that altered B-cell viability. Shifts in cytokine production from TH1 toward TH2 patterns have been noted in human T cells from patients treated with DMF. These changes in T-cell cytokine output may have contributed to the increase in regulatory B-cell subsets, since the TH2 cytokine IL-5 has been shown to preferentially stimulate growth of immune regulatory mouse B-1 B cells that expressed Fas ligand and IL-10. Further work is necessary to understand the cells and processes involved and their relative importance to the therapeutic effects of BG-12.

Direct effects of BG-12 or DMF on signal transduction in human B cells have not been previously reported. BG-12 is known to activate the nuclear factor (erythroid-derived 2)–like 2 (Nrf2) pathway in neuronal cells. Unlike the proapoptotic effects of DMF on T cells, our group recently demonstrated that activation of the Nrf2 pathway by DMF can inhibit...
neuronal cell apoptosis as a possible mechanism of neuroprotection. It will be of interest to determine whether BG-12 activates different signaling pathways and has a pro vs antiapoptotic effect on different subsets of human B cells. One product of Nrf2 activation that may play a direct role in the immune response is heme oxygenase–1 (HO-1), which is known to stimulate the functions of Treg cells. In contrast, very little is known about the role of Nrf2 and HO-1 in regulatory B-cell activation and function. It remains to be determined whether BG-12 has direct effects on proliferation or protection from apoptosis of T2-MZP or B-1 B cells. Other possibilities for the observed increases in these cell populations include indirect effects through activation of other cell populations or homeostatic proliferation response resulting from the loss of other lymphocytes.

In humans, CD24highCD38high T2-MZP and CD27+CD43+ B-1 B cells have been designated as regulatory B-cell subsets based on their ability to produce IL-10. Both the T2-MZP and B-1 B-cell subsets were increased in total cell number and percentage following long-term treatment in the majority of the patients we studied. The T2-MZP B cells responded earlier and more consistently than the B-1 B cells, suggesting that different mechanisms were involved in their proliferation. Increases in T2-MZP B cells have been noted following treatment of patients with RRMS with other medications, suggesting that these cells may be highly important in the regulation of multiple sclerosis (MS) pathogenesis.

The response among B-1 B cells in BG-12-treated patients with RRMS was more complicated and individualized, with the increase in B-1 B cells only detected after 1 year of treatment, and only in 6 of the 8 patients analyzed. This may have been due in part to the fact that the majority of these innate B cells are resident in the lining of the gut and lungs, and the delayed increase in their numbers in the blood may reflect earlier activation or proliferation in the mucosa. Most of the patients had significantly lower levels of B-1 B cells prior to treatment, in agreement with findings of other investigators. However, the previous authors concluded that treatment of patients with RRMS with glatiramer acetate, interferon-β, or natalizumab had no effect on CD43+CD27+ B-1 B cells. This was in sharp contrast to the effects of glatiramer acetate treatment in mouse EAE, which resulted in expansion and increased regulatory function of CD5+ B-1a cells. It should be noted that CD5 is not a specific marker for B-1 cells in humans, complicating the interpretation of previous reports linking human CD5+ B cells to MS pathogenesis.

We did not assess IL-10 production by intracellular staining, and therefore, were not able to determine whether the freshly isolated B cells were expressing IL-10 in vivo. The levels of IL-10 produced by 7 out of 9 of the patients with RRMS correlated with the combined percentages of T2-MZP and B-1 B cells in the sample, but not with either of the subsets independently. The data for these 7 patients contrasted with previous reports associating autoimmunity with poorly functioning regulatory B cells, and suggest that B cells in these patients with RRMS would be capable of contributing to immune regulation. Notably, B cells from 2 of the patients with RRMS in our study did not produce significant amounts of IL-10 despite having relatively high levels of T2-MZP and B-1 B cells. It will be interesting to track clinical responses in these patients long term, and to perform similar analyses on a larger population to determine whether the beneficial effects of BG-12 correlate with the activation and competence of regulatory B cells.

It should be noted that this study was done with a limited number of patients, and that continued work should be done with larger groups and longer follow-up to confirm these findings. Study of more complex variables, such as the effects of prior treatments as well as duration and severity of disease at treatment initiation, will require much larger groups and may be important in determining which patients are most likely to benefit from BG-12 therapy. An important aspect of our study is the variability of the responses of B cells to BG-12 treatment and how this may relate to clinical responses. None of these 13 patients has relapsed and there have been no new MRI lesions during this study (data not shown). The patients have tolerated BG-12 treatment well with only a few reports of minor side effects that have subsided over time. With several cases of PML having been reported, there is understandable concern about long-term effects of BG-12 and a need to screen for JC virus. None of the patients in our study have had signs of active JC virus. These issues highlight the need for more long-term studies with large cohorts of patients, which may lead to a better understanding of variables that relate not only to favorable outcomes, but also to severe negative side effects such as PML. It will be interesting to determine whether the short-term effects of BG-12 on T2-MZP or B-1 B cells will predict the long-term clinical efficacy of BG-12 treatment.

**STUDY FUNDING**

No commercial funding was received to support this work. The study was funded with institutional support from the University of Michigan Medical School.
REFERENCES

12. Matsushita T, Horikawa M, Iwata Y, Tedder TF. Regulatory T cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J Immunol 2010;185:2240–2252.

DISCLOSURE

S.K. Lundy received nonprofit honorarium from University of Connecticut, is on the editorial board for The Open Rheumatology Journal, and received research support from Merck, Chugai, NIH, University of Michigan Medical School, and Edward T. and Ellen K. Dryer Foundation. Q. Wu and Q. Wang report no disclosures. C.A. Dowling served on the scientific advisory board for, received travel funding from, and/or speaker honoraria from, and consulted for Acorda, Bayer, Biogen Idec, EMD Serono, Genzyme, Novartis, Questcor, Chugai, and Teva, and received research support from NIH NIAID and NINDS. Go to Neurology.org/nn for full disclosure forms.

Received September 25, 2015. Accepted in final form December 22, 2015.
Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets

Steven K. Lundy, Qi Wu, Qin Wang, et al.
Neurol Neuroimmunol Neuroinflamm 2016;3;
DOI 10.1212/NXI.0000000000000211

This information is current as of March 3, 2016

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/3/2/e211.full.html

References
This article cites 39 articles, 7 of which you can access for free at:
http://nn.neurology.org/content/3/2/e211.full.html##ref-list-1

Citations
This article has been cited by 2 HighWire-hosted articles:
http://nn.neurology.org/content/3/2/e211.full.html##otherarticles

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Autoimmune diseases
http://nn.neurology.org/cgi/collection/autoimmune_diseases
Multiple sclerosis
http://nn.neurology.org/cgi/collection/multiple_sclerosis

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus